LRRK2 Inhibition Differently Affects Lysosomal Hydrolase Activity and Autophagy-Related Protein Levels in PBMC-Derived Macrophages from Patients with Different Synucleinopathies
Katerina Basharova1,2,#,*, Anastasia Bezrukova1,2,#, Alena Kopytova1,2, Anna Lavrinova1,2, Galina Baydakova3, Irina Miliukhina1,4, Ekaterina Zakharova1,3, Anton Emelyanov1,2, Sofya Pchelina1,2, Tatiana Usenko1,2,*
BIOCELL, Vol.50, No.8, 2026, DOI:10.32604/biocell.2026.079585
- 27 July 2026
(This article belongs to the Special Issue: Cellular and Molecular Mechanisms in Parkinson's Disease: Novel Targets and Biomarkers for Target Therapy)
Abstract Objectives: Synucleinopathies—Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)—involve alpha-synuclein aggregation and lysosomal dysfunction. We conducted a longitudinal study of lysosomal hydrolase activities and lysosphingolipid levels in blood and PBMC-derived macrophages from patients, and assessed the effects of LRRK2 inhibition (MLi-2). Methods: Blood and PBMC-derived macrophages were collected from patients with idiopathic PD (iPD), DLB, MSA, and controls. Enzyme activities (GCase, ASMase, GLA, GALC) and lysosphingolipids (HexSph, LysoGb3, LysoSM) were measured. Autophagy markers (p62, LC3B-II) and cathepsin D (CTSD) were analyzed by western blot. Effects of MLi-2 were evaluated in macrophages. Results:… More >